CAMBRIDGE, England--(BUSINESS WIRE)--Bicycle Therapeutics Ltd, a new biotechnology company developing a novel technology platform for the identification and optimisation of chemically constrained cyclic peptides with high target specificity and binding affinity, has signed a License agreement with the Ecole Polytechnique Federale de Lausanne (EPFL) in Lausanne, Switzerland and has secured additional seed funding from SR One, the independent corporate venture fund of GlaxoSmithKline, and SV Life Sciences.
